<span item_type="fundamental" item_id="d9dbc11816b29bcb2254bc9ed78c3a32" counter_id="ST/US/NXLIW" env="prod"></span><span item_type="announcement" item_id="515731335387094017" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 41.02 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.15.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: $41,015 for the three months ended March 31, 2025, compared to $78,671 for the same period in 2024, representing a decrease of 48%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: - $1,988,337 for the three months ended March 31, 2025, compared to - $1,041,157 for the same period in 2024, an increase in net loss by 91%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li><li><strong>Gross Profit</strong>: $27,457 for the three months ended March 31, 2025, compared to $69,515 for the same period in 2024, a decrease of 61%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses were $2,038,682 for the three months ended March 31, 2025, compared to $1,143,227 for the same period in 2024, an increase of 78%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $1,426,214 for the three months ended March 31, 2025, compared to - $763,289 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: $1,473,758 for the three months ended March 31, 2025, compared to $729,314 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Device Sales</strong>: No device sales were recorded for the three months ended March 31, 2025, compared to $55,500 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Nexalin plans to conduct decentralized clinical trials for the Gen-2 SYNC and Gen-3 HALO devices in the U.S. and will continue to consult with the FDA as part of the pre-submission process. If FDA clearance is obtained, commercialization of these devices for sale in the U.S. and other territories will begin.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is developing a virtual clinic to address the stigma associated with mental health treatment, allowing physicians to diagnose and prescribe treatments in a virtual setting.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1527352/000182912625003612/nexalintechno_10q.htm"></span></li></ul>

NEXALIN TECHNOLOGY INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 41.02 K